Core Viewpoint - PharmaCorp RX Inc. has restated and refiled its financial statements for the interim period ended June 30, 2025, following a review by its Auditor, with certain accounting adjustments made that do not affect the overall financial position of the Corporation [1]. Financial Adjustments - The Amended Q2 2025 Statements show significant changes, including an increase in intangible assets from $4,847,651 to $6,937,651 and the addition of an acquired charter valued at $2,090,000 [2]. - The purchases of property and equipment were adjusted from $2,145,438 to $55,438, indicating a significant revision in asset reporting [2]. - The total assets and net cash used in investing activities remained unchanged despite these adjustments, indicating minimal impact on the overall financial health [3]. Notes and Revisions - Changes were made to the notes of the Amended Q2 2025 Statements, including a working capital adjustment for the acquisition of Atlantic Canada 1 amounting to $1,019,014 and the addition of the acquired charter as a line item [5]. - A footnote was added to clarify ownership restrictions under Ontario's Drug and Pharmacies Regulation Act, and amortization amounts were revised accordingly [5]. - Subsequent event notes were added to reflect the closing of the purchase of two pharmacies in Western Canada and one in Eastern Canada, as announced on October 2, 2025 [5]. Company Operations - PharmaCorp operates seven PharmaChoice Canada bannered pharmacies and plans to continue acquiring more pharmacies under this brand, as part of its strategic alliance with PharmaChoice Canada [4]. - The Corporation is also open to acquiring independently owned pharmacies and transitioning them to the PharmaChoice Canada banner [4]. - PharmaCorp actively seeks discussions with pharmacy owners regarding succession or sale, emphasizing a commitment to seamless transitions that protect legacies and serve communities [6].

Financial Performance - For FY25, Net Revenue increased by 38% to R53 billion, compared to R38 billion in FY24[20] - Group Adjusted EBITDA for FY25 increased by 33% to R922 million, compared to R691 million in FY24[20] - Adjusted earnings per share increased by 187% to R229 in FY25, compared to R080 in FY24[20] - For Q4 FY25, Net Revenue increased by 47% to R15 billion, compared to R10 billion in Q4 FY24[35] - Group Adjusted EBITDA for Q4 FY25 increased by 61% to R306 million, compared to R190 million in Q4 FY24[35] - Adjusted earnings per share for Q4 FY25 increased by 211% to R099, compared to R032 in Q4 FY24[35] Strategic Initiatives - The company acquired Adumo for R17 billion, Recharger for R507 million, and announced the acquisition of Bank Zero for R11 billion[26] - The company exited non-core asset MobiKwik for R290 million, using proceeds to reduce gross debt[26] FY26 Guidance - The company expects FY26 Net Revenue to be between R64 billion and R69 billion, representing a YoY growth of 21%-30%[110] - The company expects FY26 Group Adjusted EBITDA to be between R125 billion and R145 billion, representing a YoY growth of 36%-57%[110] - The company expects FY26 Adjusted EPS to be greater than R460, representing a YoY growth of over 100%[110]

Core Viewpoint - The Joint Corp. plans to restate its previously issued financial statements for 2024 and the first quarter of 2025 due to errors related to the impairment of assets held for sale, which will affect the reported net loss and carrying value of these assets [1][2][4][6]. Financial Impact - For the year ended December 31, 2024, the correction is expected to reduce the previously reported loss from discontinued operations by approximately $2.2 million, leading to a decrease in net loss and an increase in the carrying value of assets held for sale by the same amount [4]. - For the quarter ended March 31, 2025, the correction is anticipated to increase previously reported income from discontinued operations by approximately $0.5 million, resulting in a cumulative increase in the carrying value of assets held for sale by approximately $2.7 million [6]. Adjusted EBITDA - The adjustments for both the year ended December 31, 2024, and the quarter ended March 31, 2025, are not expected to impact Adjusted EBITDA or cash positions [5][7]. Internal Controls - The company is evaluating the impact of the identified errors on its internal control over financial reporting, expecting to conclude that there will be a material weakness in these controls during the applicable periods [8]. Company Overview - The Joint Corp. is the largest franchisor of chiropractic care in the U.S., operating over 950 locations and facilitating more than 14 million patient visits annually [10]. - The company has been recognized in various industry rankings, including Franchise Times' "Top 400" and Entrepreneur's "Franchise 500" [10]. Business Structure - The Joint Corp. operates as a franchisor and manages clinics in several states, providing management services to affiliated chiropractic practices [11].